Predicting which HIV patients will respond better to future therapeutic vaccine

July 18, 2014

A new study suggests that HIV patients with a higher level of a particular biomarker, or a measurable indicator found in the blood, may respond more favourably to an experimental immune activating vaccine.

Experts at St George's, University of London, and Norwegian company, Bionor Pharma Researchers, believe the findings might lead to a more customised vaccine for certain , which potentially might permit them to come off antiretrovirals, drugs used to treat HIV.

The research found that the , Vacc-4x, reduced the amount of virus circulating in the body by more than half in patients with higher levels of the particular biomarker compared to those with lower levels.

Professor Angus Dalgleish, of St George's, University of London, said: "In spite of very effective drugs against HIV these need to be taken daily and have significant side-effects.

"The ability to replace this daily medication with a vaccine that allows several months of being off medication, not to mention the enormous financial gains that would be delivered to health services, is a step closer with these preliminary results."

Further study will be needed to confirm the results.

These new results were announced today (July 18) at the AIDS 2014 Conference in Melbourne, Australia.

The results come from a collaborative project between St George's, University of London and Bionor Pharma.

In the UK nearly 78,000 people were receiving specialist care for HIV in 2012.

Explore further: Scientists discover how a killer fungus attacks HIV patients

Related Stories

Research may be beating HIV, but a vaccine remains distant

July 11, 2014

Three decades since the onset of the infection in a global population, HIV care and treatment is looking very different. Given the difficulties involved, it is remarkable that having developed good treatments, the global ...

Spanish hospital to trial new HIV treatment

December 9, 2013

Researchers at a Spanish hospital announced Monday they will start trials next year of a therapeutic vaccine for patients who already have HIV, the virus that causes AIDS.

Durable end to AIDS will require HIV vaccine development

February 5, 2014

Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

HIV vaccine research must consider various immune responses

April 3, 2014

Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility ...

Recommended for you

Study unlocks secret of common HIV strain

October 13, 2016

A discovery that the most common variant of the HIV virus is also the "wimpiest" will help doctors better treat millions of individuals around the world suffering from the deadly disease, according to one of the world's leading ...

Children could point the way to new HIV treatments

September 29, 2016

Children with HIV who can resist the disease progressing could point the way to new treatments for HIV infection that are more widely applicable to infected adults and children alike, an international team of researchers ...

Broadly neutralizing HIV antibodies pave the way for vaccine

September 26, 2016

A small number of people infected with HIV produce antibodies with an amazing effect: Not only are the antibodies directed against the own virus strain, but also against different sub-types of HIV that circulate worldwide. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.